Stock Ratings / Health Care / SPRO / forecast

CPIX (38) GOSS (33) RNTX (49) FBIO (39) ⌘ Pro Terminal →

Spero Therapeutics Inc. (SPRO) 12-Month Stock Forecast & Price Target Cone

Q: Where is SPRO trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRO last traded at $1.06 (-4.50% on volume of 309,875 shares), positioning the stock -9.40% below its 50-day simple moving average ($1.17) and -46.46% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $3.08, SPRO sits at the 1.0% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.00 to $1.19).

Q: What is SPRO's 12-month stock price target?

Spero Therapeutics Inc. (SPRO) carries a 12-month consensus base price target of $0.99 (-6.6% from $1.06), with a bull-case target of $3.23 and a bear-case floor of $0.77.

Q: Is SPRO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SPRO D- (Sell — SELL) with an RQD Confidence score of 43/100.

$1.06 -4.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.05

Spero Therapeutics Inc. (SPRO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $64.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SPRO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SPRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Spero Therapeutics Inc. (NASDAQ: SPRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.06 (-4.50% 1D, market cap $64.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, SPRO ranks #465 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SPRO compare to CPIX and GOSS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRO carries a Roarable D- (43/100 RQD), trailing P/E of 7.5x, gross margin of —, and ROIC of 26.6%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -16.4%, cap $65.2M) and GOSS (Gossamer Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SPRO?

▼

Per SPRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701108), Spero Therapeutics Inc. generated $12.6M in revenue (+3292.5% YoY), $8.6M in net income, and -$12.6M in free cash flow against $68.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.05 (-1.00%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRO)Realized 20D OHLCV Swing Band: ±11.9%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY SPRO SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Disciplined Float (+0.24% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.20-8.3% Next Q

Q2 (-2Q)

Grade D$1.10+0.9% Next Q

Q3 (-1Q)

Grade D$1.11-4.5% Next Q

Current

Grade D-$1.06-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SPRO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SPRO currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.17) and Max Pain ($1.11) forces dealer call-delta covering toward $3.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPRO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SPRO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SPRO Position Size: $10,000

Shares at $1.06: 9434.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.77

$7,264

$-2,736 (-27.4%)

12M Consensus BaseTarget $0.99

$9,340

$-660 (-6.6%)

12M Bull Case BreakoutTarget $3.23

$30,472

+$20,472 (+204.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRO)

✓Walkthrough of SPRO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPRO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.77%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.11H $1.12L $1.05C $1.06VOL 309.9K

RES: $1.59SUP: $1.03SMA50: $1.17SMA200: $1.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPRO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPRO Butterfly Map → + Track SPRO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.7%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SPRO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPRO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPRO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRO)

Health Care Rank #465 of 1016 ⚔️ CPIX vs SPRO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPRO vs. CPIX, GOSS, RNTX, FBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Spero Therapeutics Inc. (SPRO) ranks #465 by composite RQD confidence (43/100, grade D-) and #719 by equity capitalization ($64.6M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. RNTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with SPRO at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPRO ACTIVE Spero Therapeutics Inc.	D-	43/100	7.5x	—	26.6%	-4.50%	$64.6M	Benchmark Subject
CPIX Cumberland Pharmaceuticals Inc.	D-	38/100	—	85.0%	-16.4%	+7.82%	$65.2M	/cpix-vs-spro →
GOSS Gossamer Bio Inc.	E	33/100	—	—	-35.0%	-2.90%	$65.4M	/goss-vs-spro →
RNTX Rein Therapeutics Inc.	D	49/100	—	—	-35.0%	-7.79%	$62.7M	/rntx-vs-spro →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-spro →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701108

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spero Therapeutics Inc. (SPRO) reported GAAP revenue of $12.6M (+3292.5% vs. FY2024 revenue of $371.0K , and +1249.0% cumulative change since FY2023) , GAAP net income of $8.6M, operating cash flow of -$12.6M, and free cash flow of -$12.6M (+46.2% YoY). On the balance sheet, SPRO closed FY2025 with $68.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.6M	$8.6M	-$12.6M	-$12.6M	$68.9M	—
FY2024 (FY)	2024-12-31	$371.0K	-$68.6M	-$23.4M	-$23.4M	$110.5M	—
FY2023 (FY)	2023-12-31	$933.0K	$22.8M	-$33.0M	-$33.0M	—	—

3. SPRO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SPRO compare to CPIX and GOSS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SPRO?

Where is SPRO trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRO last traded at $1.06 (-4.50% on volume of 309,875 shares), positioning the stock -9.40% below its 50-day simple moving average ($1.17) and -46.46% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $3.08, SPRO sits at the 1.0% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.00 to $1.19).

SPRO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SPRO's 12-month stock price target?

Spero Therapeutics Inc. (SPRO) carries a 12-month consensus base price target of $0.99 (-6.6% from $1.06), with a bull-case target of $3.23 and a bear-case floor of $0.77.

Is SPRO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SPRO D- (Sell — SELL) with an RQD Confidence score of 43/100.

Direct Sub-Reports: SPRO RQD Cockpit SPRO 12M Forecast SPRO Earnings & Move SPRO Dividends & DRIP SPRO Insiders & 13F SPRO Whale Options SPRO Profit Sankey SPRO News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SPRO — Spero Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Spero Therapeutics Inc. (SPRO) carries a composite score of 43/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.06 (-4.50%). Fundamental cash generation scores 7/20 (ROIC 26.6%, FCF yield -19.53%), institutional 13F whale accumulation scores 6/20, insider conviction scores 11/20, macro regime alignment scores 9/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score 0.20, Piotroski F-Score 5/9).

Investor Implication: At 7.5x trailing P/E and 6.3x forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (50.2%) and free cash flow conversion relative to the 52-week range of $1.04 – $3.08.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SPRO is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

SPRO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Spero Therapeutics Inc. (SPRO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SPRO Debate Forum (3) ↓

🟡 MARKET WIRE Benzinga • 3d ago

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.

Read Full Source ↗

🟢 CATALYST Yahoo • 7d ago

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapiesDae Gon Ha, Ph.D., appointed

Read Full Source ↗

🔴 RISK WATCH Yahoo • 12d ago

Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease

Spero Therapeutics (NASDAQ:SPRO) plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief Executive Officer Esther

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 17d ago

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today

Read Full Source ↗

🟢 CATALYST Yahoo • 20d ago

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight

The complicated urinary tract infections market is expected to experience steady growth, driven by the rising prevalence of antimicrobial-resistant pathogens, increasing rates of recurrent and hospital-acquired urinary t

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SPRO Bull vs. Bear Conversation Board — What's Your Call at $1.06?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SPRO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.93 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SPRO (D- • RQD 43/100) a Buy at $1.06?

Welcome to the SPRO (Spero Therapeutics Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (26.6% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.80 (-24.5%)

Spot @ $1.06

Pump the brakes on SPRO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SPRO, but look at what you are paying: 7.5x trailing P/E with tightening sector spreads. Unless Spero Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.30 (+22.6%)

Spot @ $1.06

SPRO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SPRO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.06 (52-wk range $1.04 - $3.08), any beat on forward guidance forces shorts and underweight funds to chase.